dilazep has been researched along with Alloxan Diabetes in 2 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morikawa, A | 1 |
| Eto, M | 1 |
| Makino, I | 1 |
| Yamamoto, M | 1 |
| Fukui, M | 1 |
| Kuramoto, T | 1 |
| Kabuki, K | 1 |
| Tomino, Y | 1 |
2 other studies available for dilazep and Alloxan Diabetes
| Article | Year |
|---|---|
The effect of dilazep on urinary protein excretion in spontaneous diabetic Chinese hamster.
Topics: Animals; Basement Membrane; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetic Nephro | 1993 |
Effects of antiplatelet drug dilazep dihydrochloride on anionic sites and extracellular matrix (ECM) components in glomerular basement membrane of STZ-induced diabetic rats.
Topics: Animals; Anions; Basement Membrane; Binding Sites; Creatinine; Diabetes Mellitus, Experimental; Diab | 1995 |